08:15 AM EDT, 06/24/2024 (MT Newswires) -- Adicet Bio ( ACET ) said Monday the US Food and Drug Administration has cleared its investigational new drug application for its ADI-270 cancer therapy.

The company said it plans to start a phase 1 trial to assess the safety and anti-tumor activity of ADI-270 in relapsed/refractory renal cell carcinoma patients in H2.

Adicet shares were nearly 3% higher in premarket trading.

Price: 1.4100, Change: +0.04, Percent Change: +2.92